Eagle’s Eye View: Are There Benefits of SGLT2 Inhibitors in Both Black and White Patients with HF?
In this week’s View, Dr. Eagle looks at a patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials that investigated racial differences in quality of life for patients with heart failure treated with SGLT2 inhibitors. He then covers screening for dilated cardiomyopathy in at-risk first-degree relatives. Finally, Dr. Eagle discusses skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction.
Keywords: EaglesEyeView, Sodium-Glucose Transporter 2 Inhibitors
< Back to Listings